Cargando…
Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report
We identified a PSEN1 mutation carrier from the world’s largest autosomal dominant Alzheimer’s disease kindred who did not develop mild cognitive impairment until her seventies, three decades after the expected age of clinical onset. She had two copies of the APOE3 Christchurch (R136S) mutation, unu...
Ejemplares similares
-
Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia
por: Sepulveda-Falla, Diego, et al.
Publicado: (2022) -
Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease
por: Hanseeuw, Bernard J., et al.
Publicado: (2019) -
Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
por: Norton, Daniel J., et al.
Publicado: (2020) -
Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease
por: Guzmán-Vélez, Edmarie, et al.
Publicado: (2022) -
Gliovascular alterations in sporadic and familial Alzheimer's disease:
APOE3
Christchurch homozygote glioprotection
por: Henao‐Restrepo, Julián, et al.
Publicado: (2022)